


PRODUCT INFORMATION



Perindopril

Item No. 20796

CAS Registry No.: 82834-16-0
Formal Name: (2S,3aS,7aS)-1-[(2S)-2-[[[(1S)-1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid
MF: C₁₉H₃₂N₂O₅
FW: 368.5
Purity: ≥95%
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Perindopril is supplied as a crystalline solid. A stock solution may be made by dissolving the Perindopril in the solvent of choice, which should be purged with an inert gas. Perindopril is soluble in the organic solvent ethanol at a concentration of approximately 25 mg/ml.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of perindopril can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of perindopril in PBS, pH 7.2, is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Perindopril is an orally active angiotensin converting enzyme (ACE) inhibitor that effectively lowers blood pressure.^{1,2} It is a prodrug that is metabolized to perindoprilat (Item No. 17574), a specific, competitive inhibitor of ACE (IC₅₀ = 1.5-3.2 nM *in vitro*).³

References

1. Sennesael, J., Ali, A., Sweny, P., *et al.* The pharmacokinetics of perindopril and its effects of serum angiotensin converting enzyme activity in hypertensive patients with chronic renal failure. *Br. J. Clin. Pharmac.* **33**, 93-99 (1992).
2. Wang, J., Pimenta, E., and Chwallek, F. Comparative review of the blood pressure-lowering and cardiovascular benefits of telmisartan and perindopril. *Vasc. Health Risk Manag.* **10**, 189-200 (2014).
3. Vago, T., Bevilacqua, M., Conci, F., *et al.* Angiotensin converting enzyme binding sites in human heart and lung: Comparison with rat tissues. *British Journal of Pharmacology* **107**(3), 821-825 (1992).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/01/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM